Noga Shem‐Tov

2.7k total citations
85 papers, 1.7k citations indexed

About

Noga Shem‐Tov is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Noga Shem‐Tov has authored 85 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Hematology, 34 papers in Oncology and 20 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Noga Shem‐Tov's work include Hematopoietic Stem Cell Transplantation (49 papers), Acute Myeloid Leukemia Research (37 papers) and Acute Lymphoblastic Leukemia research (20 papers). Noga Shem‐Tov is often cited by papers focused on Hematopoietic Stem Cell Transplantation (49 papers), Acute Myeloid Leukemia Research (37 papers) and Acute Lymphoblastic Leukemia research (20 papers). Noga Shem‐Tov collaborates with scholars based in Israel, United States and Italy. Noga Shem‐Tov's co-authors include Arnon Nagler, Avichai Shimoni, Ronit Yerushalmi, Abraham Avigdor, Izhar Hardan, Ivetta Danylesko, Moshe Yeshurun, I Ben-Bassat, Roni Shouval and Ayelet Dar and has published in prestigious journals such as Blood, Cancer and Cancer Research.

In The Last Decade

Noga Shem‐Tov

79 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noga Shem‐Tov Israel 23 1.0k 584 409 291 241 85 1.7k
Ronit Yerushalmi Israel 24 1.0k 1.0× 772 1.3× 435 1.1× 407 1.4× 193 0.8× 105 1.9k
Richard Champlin United States 19 1.1k 1.0× 638 1.1× 428 1.0× 251 0.9× 161 0.7× 52 1.7k
Edward Kanfer United Kingdom 26 1.1k 1.1× 477 0.8× 250 0.6× 416 1.4× 175 0.7× 55 1.8k
Andrew R. Rezvani United States 20 862 0.8× 527 0.9× 218 0.5× 413 1.4× 361 1.5× 72 1.6k
Diane Coso France 25 929 0.9× 582 1.0× 278 0.7× 309 1.1× 376 1.6× 78 1.7k
Alfonso Piciocchi Italy 25 1.0k 1.0× 488 0.8× 682 1.7× 208 0.7× 353 1.5× 105 1.8k
Aleksandr Lazaryan United States 21 678 0.6× 797 1.4× 200 0.5× 443 1.5× 275 1.1× 103 1.7k
Margit Mitterbauer Austria 25 1.1k 1.0× 298 0.5× 272 0.7× 462 1.6× 170 0.7× 67 1.7k
Deok‐Hwan Yang South Korea 20 488 0.5× 437 0.7× 203 0.5× 279 1.0× 386 1.6× 124 1.3k
Jean‐Pierre Jouet France 17 1.5k 1.5× 443 0.8× 379 0.9× 372 1.3× 121 0.5× 39 1.9k

Countries citing papers authored by Noga Shem‐Tov

Since Specialization
Citations

This map shows the geographic impact of Noga Shem‐Tov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noga Shem‐Tov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noga Shem‐Tov more than expected).

Fields of papers citing papers by Noga Shem‐Tov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noga Shem‐Tov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noga Shem‐Tov. The network helps show where Noga Shem‐Tov may publish in the future.

Co-authorship network of co-authors of Noga Shem‐Tov

This figure shows the co-authorship network connecting the top 25 collaborators of Noga Shem‐Tov. A scholar is included among the top collaborators of Noga Shem‐Tov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noga Shem‐Tov. Noga Shem‐Tov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shouval, Roni, Shalev Fried, Ivetta Danylesko, et al.. (2025). Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells. Blood Advances. 9(7). 1720–1725. 1 indexed citations
2.
Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2024). Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Current Research in Translational Medicine. 72(4). 103471–103471. 5 indexed citations
3.
Youngster, Ilan, Ivetta Danylesko, Israel Henig, et al.. (2024). Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study. Bone Marrow Transplantation. 59(3). 409–416. 7 indexed citations
4.
Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2023). P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION. HemaSphere. 7(S3). e4369964–e4369964. 1 indexed citations
5.
Magen, Hila, Shalev Fried, Orit Itzhaki, et al.. (2023). POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA. Hematological Oncology. 41(S2). 82–83. 1 indexed citations
6.
Fried, Shalev, Ivetta Danylesko, Orit Itzhaki, et al.. (2023). High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia. Blood. 142(Supplement 1). 6875–6875.
7.
Fried, Shalev, Orit Itzhaki, Ronit Yerushalmi, et al.. (2023). Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Leukemia & lymphoma. 64(12). 1956–1963. 3 indexed citations
8.
Shouval, Roni, Shalev Fried, Ivetta Danylesko, et al.. (2023). Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy. Blood. 142(Supplement 1). 3519–3519. 2 indexed citations
9.
Kedmi, Meirav, Roni Shouval, Shalev Fried, et al.. (2022). Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplantation and Cellular Therapy. 28(5). 251–257. 24 indexed citations
10.
Fried, Shalev, Roni Shouval, Nira Varda‐Bloom, et al.. (2022). Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leukemia & lymphoma. 63(14). 3385–3393. 5 indexed citations
11.
Danylesko, Ivetta, Roni Shouval, Noga Shem‐Tov, et al.. (2020). Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation. 56(5). 1134–1143. 23 indexed citations
12.
Shouval, Roni, Joshua Fein, Ivetta Danylesko, et al.. (2019). Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. European Journal Of Haematology. 103(4). 402–409. 37 indexed citations
13.
Fein, Joshua, Avichai Shimoni, Myriam Labopin, et al.. (2018). The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 32(8). 1787–1794. 31 indexed citations
14.
Shouval, Roni, Joshua Fein, Ivetta Danylesko, et al.. (2017). Determinants for Oral Mucositis in Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Evaluation and Risk Analysis. Blood. 130. 3239–3239. 1 indexed citations
15.
Tsirigotis, Panagiotis, Ivetta Danylesko, Noga Shem‐Tov, et al.. (2016). Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplantation. 51(10). 1313–1317. 21 indexed citations
16.
Danylesko, Ivetta, Nira Varda‐Bloom, Ronit Yerushalmi, et al.. (2015). Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study. Acta Haematologica. 135(1). 29–36. 8 indexed citations
17.
18.
Shimoni, Avichai, Noga Shem‐Tov, Yulia Volchek, Ronit Yerushalmi, & Arnon Nagler. (2011). Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced. Blood. 118(21). 655–655. 1 indexed citations
19.
Shimoni, Avichai, Izhar Hardan, Noga Shem‐Tov, et al.. (2008). 158: Relapse of Acute Myeloid Leukmia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning is Associated with Longer Survival than Relapse after Reduced-Intensity Conditioning (RIC). Biology of Blood and Marrow Transplantation. 14(2). 59–60. 1 indexed citations
20.
Lahav, Meir, Orit Uziel, Meir Kestenbaum, et al.. (2005). Nonmyeloablative Conditioning Does Not Prevent Telomere Shortening after Allogeneic Stem Cell Transplantation. Transplantation. 80(7). 969–976. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronit Yerushalmi Breakdown of academic impact, for papers by Richard Champlin Breakdown of academic impact, for papers by Edward Kanfer Breakdown of academic impact, for papers by Andrew R. Rezvani Breakdown of academic impact, for papers by Diane Coso Breakdown of academic impact, for papers by Alfonso Piciocchi Breakdown of academic impact, for papers by Aleksandr Lazaryan Breakdown of academic impact, for papers by Margit Mitterbauer Breakdown of academic impact, for papers by Deok‐Hwan Yang Breakdown of academic impact, for papers by Jean‐Pierre Jouet
Rankless by CCL
2026